Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apricus Biosciences has released data from animal studies showing that the NexACT technology improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.
Subscribe to our email newsletter
Apricus Bio said that a total of 10 small molecule therapeutic drugs with known low solubility and/or permeability, according to the Biopharmaceuticals (BCS) Classification System, were selected for these studies, and represented the anti-inflammatory drugs, diuretics, anti-hypertensives, antibiotics, anti-psychotics, anti-Parkinson agents and proton pump inhibitors.
Apricus Bio president and CEO Bassam Damaj said that the early data shows that the inclusion of NexACT can improve the oral delivery of some small molecules by positively affecting their solubility, which affects absorption.
"Over time, this could open up exciting new partnership opportunities, especially for promising drug candidates that did not reach, or successfully pass through clinical development, because of poor solubility," Damaj said.
"Our goal is to make a major breakthrough in the utilis ation of NexACT to improve and/or enable the delivery of difficult-to-absorb compounds."